Neuralink, a brain-chip startup, successfully implanted its device in the first human patient on Sunday, as announced by founder Elon Musk. Musk reported promising initial results, including neuron spike detection, which is vital for brain and body communication.
The U.S. FDA approved Neuralink’s human trial last year, a significant step toward the company’s goal of assisting patients with paralysis and neurological disorders. The trial, known as the PRIME Study, focuses on safety evaluations of both the implant and the surgical robot.
Neuralink aims to enable thought-controlled computer interactions through its “ultra-fine” thread implants. The company’s first product, Telepathy, will exemplify this technology.
Despite its progress, Neuralink has faced scrutiny over safety, including a recent fine for violating DOT hazardous material transport rules. Lawmakers have also urged an SEC investigation into Musk’s investor communications after reports of adverse effects in animal trials.
Musk addressed these concerns and assured on social media that no monkey fatalities were directly linked to Neuralink implants, emphasizing the use of terminal subjects to reduce risks to healthy ones.
